Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events
…, S Snapinn, KE Harris, P Aurup, JM Edelman… - Jama, 2004 - jamanetwork.com
ContextElectrocardiographic left ventricular hypertrophy (LVH) is a strong predictor of
cardiovascular (CV) morbidity and mortality. However, the predictive value of changes in the …
cardiovascular (CV) morbidity and mortality. However, the predictive value of changes in the …
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) …
…, J Rokkedal, KE Harris, JM Edelman… - Circulation, 2004 - Am Heart Assoc
Background— An echocardiographic substudy of the Losartan Intervention for Endpoint
Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left …
Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left …
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial
…, JM Stocks, BC Stoel, L Huang, Z Yao, JM Edelman… - The Lancet, 2015 - thelancet.com
Background The efficacy of α1 proteinase inhibitor (A1PI) augmentation treatment for α1
antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-…
antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-…
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
…, S Oparil, H Wedel, P Aurup, JM Edelman… - Journal of …, 2002 - journals.lww.com
Background There has been uncertainty about the risk of new-onset diabetes in hypertensive
individuals treated with different blood pressure-decreasing drugs. Objectives To study this …
individuals treated with different blood pressure-decreasing drugs. Objectives To study this …
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension
…, S Julius, LH Lindholm, MS Nieminen, JM Edelman… - Jama, 2006 - jamanetwork.com
ContextAtrial fibrillation (AF) is associated with increased risk of mortality and cardiovascular
events, particularly stroke, making prevention of new-onset AF a clinical priority. Although …
events, particularly stroke, making prevention of new-onset AF a clinical priority. Although …
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention For Endpoint reduction in Hypertension (LIFE) …
…, S Snapinn, KE Harris, P Aurup, JM Edelman… - Circulation, 2003 - Am Heart Assoc
Background— Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular
morbidity and mortality, and regression of ECG LVH may predict improved prognosis in …
morbidity and mortality, and regression of ECG LVH may predict improved prognosis in …
Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: a randomized, double-blind trial
JM Edelman, JA Turpin, EA Bronsky… - Annals of internal …, 2000 - acpjournals.org
Background: Montelukast, an oral, once-daily leukotriene receptor antagonist, provides
protection against exercise-induced bronchoconstriction. Objective: To evaluate the effect of 8 …
protection against exercise-induced bronchoconstriction. Objective: To evaluate the effect of 8 …
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID …
…, MA Tortorici, M Fries, JM Edelman… - The Lancet …, 2017 - thelancet.com
Background Purified α1 proteinase inhibitor (A1PI) slowed emphysema progression in patients
with severe α1 antitrypsin deficiency in a randomised controlled trial (RAPID-RCT), which …
with severe α1 antitrypsin deficiency in a randomised controlled trial (RAPID-RCT), which …
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy
Background Although higher heart rate (HR) at baseline has been associated with an increased
risk of cardiovascular (CV) and all-cause mortality, the relationship of in-treatment HR …
risk of cardiovascular (CV) and all-cause mortality, the relationship of in-treatment HR …
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies
…, PA Lyle, SM Snapinn, Z Zhang, JM Edelman… - The American journal of …, 2005 - Elsevier
We sought to study the risk factors for heart failure (HF) and the relation between antihypertensive
treatment with losartan and the first hospitalization for HF in patients with diabetes …
treatment with losartan and the first hospitalization for HF in patients with diabetes …